Crispr gene-editing technology has demonstrated its revolutionary potential in recent years: It has been used to treat rare diseases, to adapt crops to withstand the extremes of climate change, or ...

Sirius Therapeutics and CRISPR Therapeutics have dosed the first patient in a Phase II trial of SRSD107 for thromboembolic disorders in Europe. This trial aims to investigate SRSD107 in preventing ...

The company is gene editing crops to make our food supply more resilient to climate change. Climate change will make it increasingly difficult to grow crops across many parts of the world. Pairwise is ...